SGLT-2 Inhibitors and Circulating Progenitor Cells in Diabetes.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 32302526.
- Also identified by DOI 10.1016/j.cmet.2020.04.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hess et al. recently hypothesized that shifts in circulating progenitor cell populations may drive cardiovascular protection by SGLT-2 inhibitors in patients with type 2 diabetes. In this Letter, Fadini challenges that interpretation and discusses previous findings from an independent randomized placebo-controlled trial indicating that cardiovascular protection by SGLT-2 inhibitors may not directly involve circulating stem/progenitor cells.
Medical subject headings
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors